{"id":2486,"date":"2022-10-04T13:21:49","date_gmt":"2022-10-04T13:21:49","guid":{"rendered":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics\/?page_id=2486"},"modified":"2026-04-28T17:15:40","modified_gmt":"2026-04-28T17:15:40","slug":"publications","status":"publish","type":"page","link":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"\n
<\/div><\/div><\/div>

Posters & Publications<\/strong><\/span><\/h1>\n<\/div><\/div>

Nalbuphine Tablets for Cough in Patients with Idiopathic Pulmonary Fibrosis<\/a><\/span><\/h4>\n

Maher TM et al.,\u00a0NEJM Evidence<\/em>\u00a0(2023)<\/p>\n<\/div><\/div>

The Role of Kappa-Opioid and Mu-Opioid Receptors in Pruritus: Peripheral and Central Itch Circuits<\/a><\/span><\/h4>\n

Kim BS et al.,\u00a0Exp Dermatol.<\/em>\u00a0(2022)<\/p>\n<\/div><\/div>

Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications<\/a><\/span><\/h4>\n

Elmariah et al.,\u00a0Journal of the American Academy of Dermatology (JAAD) International<\/em>\u00a0(2021)<\/p>\n<\/div><\/div>

Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase<\/a><\/span><\/h4>\n

Weisshaar E. et al.,\u00a0Journal of The European Academy of Dermatology and Venereology<\/em>\u00a0(2021)<\/p>\n<\/div><\/div>

Prevalence, Incidence, and Presence of Comorbidities in Patients with Prurigo and Pruritus in Germany: A Population-Based Claims Data Analysis<\/a><\/span><\/h4>\n

Augustin et al.,\u00a0Journal of The European Academy of Dermatology and Venereology<\/em>\u00a0(2021)<\/p>\n<\/div><\/div>

Safety and Pharmacokinetics of Nalbuphine Following Administration of Nalbuphine ER Tablets in Subjects With Impaired Hepatic Function<\/a><\/span><\/h4>\n

Rohatagi S. et al.,\u00a0Poster Presentation at European Society for Dermatological Research (ESDR) 50th Annual Meeting<\/em>\u00a0(2021)<\/p>\n<\/div><\/div>

The Role of Kappa- and Mu- Opioid Receptors in Pruritus <\/a><\/span><\/h4>\n

as presented at Maui Derm for Dermatologists 2021<\/p>\n<\/div><\/div>

Modulation of the Mu and Kappa Opioid Axis for Treatment of Chronic Pruritus<\/a><\/span><\/h4>\n

as presented at Maui Derm for Dermatologists 2021<\/p>\n<\/div><\/div>

Prevalence of prurigo nodularis in the United States of America: A retrospective database analysis<\/a><\/span><\/h4>\n

St\u00e4nder et al.,\u00a0The American Academy of Dermatology (JAAD) International<\/em> (2020)<\/p>\n<\/div><\/div>

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus<\/a><\/span><\/h4>\n

as presented at the 2020 Fall Clinical Dermatology Conference<\/p>\n<\/div><\/div>

Efficacy and Safety of Oral Nalbuphine Extended Release in Prurigo Nodularis: Results of a Phase 2, Randomized, Controlled Trial with an Open-Label Extension Phase<\/a><\/span><\/h4>\n

as presented at the 2020 Fall Clinical Dermatology Conference<\/p>\n<\/div><\/div>

Prevalence of Prurigo Nodularis in Poland<\/a><\/span><\/h4>\n

Reich and Ryczek,\u00a0Acta Dermato Venereologica<\/em> (2020)<\/p>\n<\/div><\/div>

Prevalence of Prurigo Nodularis in the United States: Findings of a Retrospective Database Analysis<\/a><\/span><\/h4>\n

as presented at the 2020 AAD Annual Meeting<\/p>\n<\/div><\/div>

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of\u00a0Nalbuphine\u00a0ER Tablets for Uremic\u00a0Pruritus<\/a><\/span><\/h4>\n

Mathur et al., American Journal of Nephrology<\/em> (2017)<\/p>\n<\/div><\/div>

Nalbuphine ER Tablets in Hemodialysis Patients with Severe Uremic Pruritus: Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial<\/a><\/h4>\n

as presented at the National Kidney Foundation Spring 2016 Meeting.<\/p>\n<\/div><\/div>

Long-Term Effects of Nalbuphine ER Tablets in Hemodialysis Patients with Uremic Pruritus: A Multicenter Open-Label Trial<\/a><\/h4>\n

as presented at the National Kidney Foundation Spring 2016 Meeting.<\/p>\n<\/div><\/div>

Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus<\/a><\/h4>\n

Hawi, et al, BMC Nephrology <\/em>(2015)<\/p>\n<\/div><\/div>

Pharmacokinetics of nalbuphine hydrochloride proof-of-concept study with pharmacokinetics demonstrating anti-pruritic activity of oral nalbuphine in hemodialysis patients with uremic pruritus<\/a><\/h4>\n

as presented at the 2014 Meeting of the Society for Investigative Dermatology.<\/p>\n<\/div><\/div>

Pharmacokinetics of Nalbuphine Hydrochloride Extended Release Tablets in Hemodialysis and Healthy Subjects following Multiple Escalating Oral Doses<\/a><\/h4>\n

as presented at the 2014 Meeting of the American College of Pharmacology.<\/p>\n<\/div><\/div>

Exploring Clinical and Pharmacological Effects of Nalbuphine HCl Oral Tablets in Hemodialysis Subjects with Pruritus<\/a><\/h4>\n

as presented at\u00a0American Society of Nephrology\u2019s 2014 Kidney Week.<\/p>\n<\/div><\/div>

Nalbuphine attenuates itch in the substance\u00a0P-induced mouse model<\/a><\/h4>\n

as presented at\u00a07th World Congress on Itch (2013).<\/p>\n<\/div><\/div>

VIEW NEWS<\/a><\/div><\/div>
<\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics\/wp-json\/wp\/v2\/pages\/2486"}],"collection":[{"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics\/wp-json\/wp\/v2\/comments?post=2486"}],"version-history":[{"count":21,"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics\/wp-json\/wp\/v2\/pages\/2486\/revisions"}],"predecessor-version":[{"id":3286,"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics\/wp-json\/wp\/v2\/pages\/2486\/revisions\/3286"}],"wp:attachment":[{"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics\/wp-json\/wp\/v2\/media?parent=2486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}